Acute Myocardial Infarction, Coronary Artery Disease
Conditions
Keywords
Myocardial Infarction, Left Ventricular Mural Thrombus, Low Molecular Weight Heparin, Enoxaparin, Warfarin, Echocardiograms
Brief summary
To prospectively evaluate the utility of enoxaparin vs. oral warfarin in reduction of echocardiographic indices of LV mural thrombus. The primary outcome is the presence of LV mural thrombus at 3.5 months. The secondary outcome is cost analysis comparing the two arms.
Detailed description
Patients with anterior Q-wave MIs and ejection fractions\<=40% will be enrolled within the first 4 days of infarction. Patients will be randomized to receive either enoxaparin 1mg/kg (maximum 100mg) subcutaneously every 12 hours for one month or heparin followed by oral warfarin for 3 months. Clinical and safety evaluations, 2-D echocardiograms at baseline and at 3.5 months and cost analysis will be performed.
Interventions
DRUGEnoxaparin
Sponsors
Rhone-Poulenc Rorer
Corewell Health East
Study design
Allocation
RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
PREVENTION
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
* Age 18 to 80 * Anterior myocardial infarction with: 1. Pathological Q-waves in at least 3 contiguous anterior precordial leads, assumed to be new 2. CK peak\>5 times the upper limit of normal with positive MB bands * Ejection fraction \<=40% or anterior dyskinesis or documented LV Thrombus * MI onset \< 7 days from randomization
Exclusion criteria
* Inability to give written informed consent * Medical conditions that would prohibit discharge within 48 hours with the exception of need for anticoagulation * Cardiogenic shock, rest angina unresponsive to medical therapy or serious ventricular arrhythmia in the 24 hours prior to randomization * Patients scheduled for surgical procedure in the next 4 months that would prevent use of enoxaparin or warfarin * Anemia: Baseline Hgb\<=9 gm for women, \<=10 gm for men or platelet count\<100,000 * Renal insufficiency (creatinine \>2.0 mg/dl) * Serious liver disease as reflected by INR\>1.3 * Stroke within past 6 months or a prior documented intracranial or subarachnoid hemorrhage * Active bleeding or major surgery within 2 weeks prohibiting the use of anticoagulants * Acute pericarditis * Women of childbearing potential unless pregnancy test negative * Cardiac or non-cardiac condition with expected survival\< 6 months * Severe peripheral vascular disease * Patients who undergo cardiac surgery, including CABG, as a result of their index myocardial infarction * Allergy to aspirin, heparin or warfarin, pork or pork products * History of recurrent thromboembolic disease or a history of Protein C, Protein S, antithrombin III deficiency or known bleeding disorder. * Current use of warfarin or need for chronic anticoagulation * Current participation in other trials using investigational drugs or devices * Prior enrollment in this trial
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| What is the incidence of LV mural thrombus with administration of enoxaparin vs. | — |
| warfarin at 3.5 months in patients presenting with anterior wall myocardial | — |
| infarctions. | — |
Secondary
| Measure | Time frame |
|---|---|
| What are the associated costs and length of hospital stay after randomized to | — |
| enoxaparin vs. warfarin? | — |
Countries
United States
Outcome results
None listed